The NorKet Study

Contribution of norketamine to ketamine-induced antinociception, and cardiovascular and neurocognitive effects. A randomized, placebo-controlled, crossover study on the influence of rifampicine on ketamine-induced effects in healthy volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27795

Enrollment

Registered

2008-05-27

Start date

2008-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacology Pain Healthy volunteers

Interventions

The NorKet study consists of 2 studies: study A and study B. 15 volunteers will take part in study A. They will be admitted twice, with at least 3 weeks in between, at our human laboratory for 1 day d

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy male subjects.

Exclusion criteria

Exclusion criteria: 1. Obesity (BMI > 30); 2. Presence of medical disease (heart-, lung-, liver-, kidney-, neurologic disease; diabetes m.; pyrosis; diaphragmatic hernia); 3. Presence of psychiatric disease; 4. History of chronic alcohol or illicit drug use; 5. Allergy to study medications; 6. Color blindness; 7. Use of contact lenses.

Design outcomes

Primary

Measure	Time frame
Analgetic effect using a heat pain model	—

Secondary

Measure	Time frame
Neurocognitive measurements(www.cnsvs.com) or; Pharmacokinetic/pharmacodynamic analyses	—

Contacts

Public ContactAlbert Dahan

Leiden University Medical Center (LUMC), Department of Anesthesiology, P.O. Box 9600

a.dahan@lumc.nl+31 (0)71 5262301

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)